The life of Cipla, the Indian pharma giant, can broadly be divided into three parts: the first 8 decades of altruistic ...

In a press release issued after market hours on February 20, Cipla announced that it has received approval for Nilotinib ...

Nomura has a Buy rating on Cipla after the company's MD reassured that the competitiveness of the Indian generics biz won't ...

Cipla has received final US FDA approval for its Nilotinib Capsules (50 mg, 150 mg, 200 mg) for the treatment of Philadelphia ...

Nilotinib is an FDA approved drug used for the treatment of Philadelphia Chromosome Positive CML, which is a cancer of blood ...

India, often dubbed the "pharmacy of the world", is among the top exporters to the U.S., especially for cheaper versions of ...

Cipla announced that it has received final approval from the United States Food and Drug Administration (USFDA) for the new drug application (NDA) submitted for 'Nilotinib Capsules 50, 150 and 200 mg' ...

India's Cipla beats Q3 profit view as strong domestic ... joint venture with Nestle India and Nicotinell acquisition, the company said on Tuesday. India's Dr Reddy's Q2 profit drops on acquisition ...

Welcome to the Cipla Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

During the year, the Company issued and allotted 2,16,469 equity shares of Rs. 2/- each to its employees under the Employee Stock Option Scheme 2013-A and the Cipla Employee StockAppreciation ...

Cipla's stock settled 2.2% higher at ₹1,427 on Tuesday on the National Stock Exchange. The company expects to launch its breast cancer drug Abraxane, which was originally slated for a rollout in ...